---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-082116"
form_type: "8-K"
ticker: "MTVA"
cik: "0001638287"
company_name: "MetaVia Inc."
filed_at: "2026-07-09T12:35:31+00:00"
generated_at: "2026-07-09T12:40:04.844908+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# MetaVia completes dose titration in Phase 1 Part 3 of DA-1726 obesity trial; topline data on track for Q4 2026

## Summary
- All active patients in Part 3A (48 mg) and Part 3B (64 mg) reached highest target doses after titration.
- Prior Phase 1 MAD data showed 9.1% mean weight loss at 48 mg in 8 weeks, plus reductions in waist circumference and glycemic measures.
- Part 3 enrolls ~40 obese subjects randomized 4:1 active:placebo across two 16-week titration cohorts.
- Topline data from Part 3 remains on track for release in Q4 2026.
- CEO cites favorable tolerability and efficient titration as potential competitive advantage over marketed obesity therapies.

## SEC filing metadata
- accession: 0001104659-26-082116
- form_type: 8-K
- ticker: MTVA
- cik: 0001638287
- company_name: MetaVia Inc.
- filed_at: 2026-07-09T12:35:31+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1638287/000110465926082116/0001104659-26-082116-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1638287/000110465926082116/tm2620006d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-082116
- JSON: https://secwatch.observer/filing/0001104659-26-082116.json
- Plain text: https://secwatch.observer/filing/0001104659-26-082116.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.